SI-BONE (SIBN) Aktievy
SI-BONE, Inc. är ett medicintekniskt företag som utvecklar procedurlösningar för skadat ben, baserade på expertis inom biomekanisk design och anatomispecifika tillämpningar i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
SIBN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
SI-BONE, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$17.56 |
| 52 veckors högsta | US$21.89 |
| 52 veckors lägsta | US$11.48 |
| Beta | 0.67 |
| 1 månads förändring | 14.25% |
| 3 månaders förändring | 36.76% |
| 1 års förändring | 2.09% |
| 3 års förändring | -32.75% |
| 5 års förändring | -40.41% |
| Förändring sedan börsintroduktionen | -12.46% |
Senaste nyheter och uppdateringar
SIBN: Raised 2026 Revenue Guidance Will Support Further Upside Potential
Analysts kept their $18.00 price target for SI-BONE steady, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and forward P/E, without a clear shift in overall conviction. What's in the News SI-BONE issued raised earnings guidance for 2026, with worldwide revenue now expected in a range of $230 million to $233 million, compared with prior guidance of $228.5 million to $232.5 million.SIBN: 2026 Guidance And Trauma Partnership Will Drive Further Upside
Analysts have trimmed their price target on SI-BONE from $22.00 to $18.00 as updated assumptions now reflect slightly lower revenue growth, a modestly reduced profit margin outlook, and a lower future P/E multiple, partly offset by a small adjustment to the discount rate. What's in the News SI-BONE issued earnings guidance for 2026, with worldwide revenue expected in a range of $228.5 million to $232.5 million, implying year-over-year growth of about 14% to 16% (Key Developments).Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...Recent updates
SIBN: Raised 2026 Revenue Guidance Will Support Further Upside Potential
Analysts kept their $18.00 price target for SI-BONE steady, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and forward P/E, without a clear shift in overall conviction. What's in the News SI-BONE issued raised earnings guidance for 2026, with worldwide revenue now expected in a range of $230 million to $233 million, compared with prior guidance of $228.5 million to $232.5 million.SIBN: 2026 Guidance And Trauma Partnership Will Drive Further Upside
Analysts have trimmed their price target on SI-BONE from $22.00 to $18.00 as updated assumptions now reflect slightly lower revenue growth, a modestly reduced profit margin outlook, and a lower future P/E multiple, partly offset by a small adjustment to the discount rate. What's in the News SI-BONE issued earnings guidance for 2026, with worldwide revenue expected in a range of $228.5 million to $232.5 million, implying year-over-year growth of about 14% to 16% (Key Developments).Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...SIBN: 2026 Guidance And Trauma Partnership Will Support Further Upside
Analysts have kept SI-BONE's price target steady at $22.00, citing only modest tweaks to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions, rather than any major change in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac joint fusion, expanding access to these products through Smith+Nephew's trauma portfolio and SI-BONE's existing sales channel (Key Developments).SIBN: 2026 Outlook And Pelvic Fixation Partnership Will Support Upside
Analysts now hold their price target for SI-BONE steady at $22.00. This reflects only small tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially shift their overall valuation view.SIBN: 2026 Revenue Outlook And Pelvic Fixation Deal Will Support Upside
Analysts have held their SI-BONE price target steady at $22.00, with only modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E, reflecting fine tuning rather than a shift in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac (SI) joint fusion, broadening access to these products through Smith+Nephew's trauma channel alongside SI-BONE's existing salesforce (Key Developments).SIBN: 2026 Revenue Outlook And New Distribution Deal Will Support Upside
Analysts have trimmed their price target for SI-BONE from $23.00 to $22.00, reflecting updated assumptions that include slightly lower revenue growth expectations, a modestly higher profit margin outlook, and a revised forward P/E multiple. What's in the News SI-BONE issued earnings guidance for 2026, projecting worldwide revenue in a range of $228.5 million to $232.5 million, with implied year over year growth guidance of about 14% to 16% (company guidance).SIBN: Higher 2025 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value estimate for SI-BONE at $23.00. They made small adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this reaffirmed target.SIBN: Raised 2025 Revenue Guidance Will Drive Stronger Profitability And Share Price Upside
Analysts have modestly lowered their price target on SI-BONE to 23.00 dollars per share, reflecting a slightly higher discount rate and a marginally lower expected future price to earnings multiple, even as they factor in stronger long term revenue growth prospects. What's in the News SI-BONE raised its 2025 revenue guidance to a range of 198 million to 200 million dollars, up from 195 million to 198 million dollars previously.SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside
Analysts have raised their price target on SI-BONE from 20 dollars to 23 dollars, citing slightly stronger expectations for revenue growth, profitability, and long term valuation multiples. What's in the News Company raised 2025 revenue guidance to a range of 198 million dollars to 200 million dollars, up from a prior range of 195 million dollars to 198 million dollars, signaling increased confidence in demand trends (company guidance filing) The updated outlook implies faster top line growth than previously anticipated and supports analysts' upward revisions to price targets and long term valuation assumptions (company guidance filing) The narrowing of the revenue guidance range suggests greater visibility into procedure volumes and commercial execution for the remainder of the year (company guidance filing) Valuation Changes The fair value estimate has risen slightly from 20 dollars to 23 dollars per share, reflecting modestly stronger growth and profitability assumptions.Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.1x may not look like an appealing investment...Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) investors will be delighted, with the company turning in some strong numbers with its...Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders would be excited to see that the share price has had a great month, posting...SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
TORQ And TNT Will Expand Market Reach In 2025
Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders have had their patience rewarded with a 26% share price jump in the last...Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues
There wouldn't be many who think SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 3.7x is worth a...Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.8x might make it look like a sell right now...Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
It's been a sad week for SI-BONE, Inc. ( NASDAQ:SIBN ), who've watched their investment drop 14% to US$17.35 in the...Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is SI-BONE (NASDAQ:SIBN) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Aktieägarnas avkastning
| SIBN | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | 2.6% | -1.3% | 0.7% |
| 1Y | 2.1% | -18.6% | 20.6% |
Avkastning vs industri: SIBN översteg US Medical Equipment branschen som gav -19.9 % under det senaste året.
Avkastning vs Marknaden: SIBN presterade sämre än US marknaden som gav 19.5 % under det senaste året.
Prisvolatilitet
| SIBN volatility | |
|---|---|
| SIBN Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: SIBN har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: SIBN s veckovolatilitet ( 9% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2008 | 376 | Laura Francis | si-bone.com |
SI-BONE, Inc. är ett medicintekniskt företag som utvecklar behandlingslösningar för skadat ben, baserade på expertis inom biomekanisk design och anatomispecifika tillämpningar i USA och internationellt. Företaget erbjuder en serie patenterade titanimplantat och de instrument som används för att implantera dem, samt implanterbara benprodukter. Företaget erbjuder också IFUSE, ett triangulärt titanimplantat med triangulärt tvärsnitt och porös yta som stabiliserar leden och underlättar biologisk fixering av benet på implantatet för att driva fusion; IFUSE 3D, ett triangulärt titanimplantat med porös yta och fenestrerad design för självskörd av ben; IFUSE BONE, som stöder och förstärker patientens egen benvävnad vid ortopediska ingrepp; IFUSE TORQ, ett additivt tillverkat gängat implantat utformat för att möjliggöra osteointegration, eller inkorporering av benet i implantatets porösa yta och struktur; IFUSE BEDROCK GRANITE, ett implantat med en maskinbearbetad titankärna och en tulpan som fästs på staven och ger fusion och fixering till den sakroiliakala leden som ett grundläggande element för segmentell spinal fusion; och IFUSE TORQ TNT, en porös gängad design med längder som kan sträcka sig över det bakre bäckenet, passera genom det ipsilaterala ilium, korsbenet och genom det kontralaterala ilium.
SI-BONE, Inc. Sammanfattning av grunderna
| SIBN grundläggande statistik | |
|---|---|
| Börsvärde | US$772.56m |
| Vinst(TTM) | -US$16.70m |
| Intäkter(TTM) | US$206.22m |
Är SIBN övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| SIBN resultaträkning (TTM) | |
|---|---|
| Intäkter | US$206.22m |
| Kostnad för intäkter | US$42.10m |
| Bruttovinst | US$164.13m |
| Övriga kostnader | US$180.82m |
| Intäkter | -US$16.70m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.38 |
| Bruttomarginal | 79.59% |
| Nettovinstmarginal | -8.10% |
| Skuld/egenkapitalförhållande | 19.9% |
Hur har SIBN utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/10 07:56 |
| Aktiekurs vid dagens slut | 2026/07/10 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
SI-BONE, Inc. bevakas av 14 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Caitlin Cronin | Canaccord Genuity |
| Citi Research | Citigroup Inc |